The perverse incentive identified in the PMC literature is worth stating explicitly: companies that can protect a high-revenue injectable molecule from generic competition by making it device-intensive have a financial reason to do so that is independent of any clinical logic
To view or add a comment, sign in New Evidence: Tirzepatide Shows Stronger Kidney Protection Than Dulaglutide in Type 2 Diabetes A major exploratory analysis from the SURPASSCVOT trial, published in The Lancet Diabetes & Endocrinology (2026), provides the first direct randomized comparison of tirzepatide vs dulaglutide on kidney outcomes in people with type 2 diabetes and established ASCVD
According to the method disclosed by the invention, the crude semaglutide is prepared by carrying out liquid-phase one-step reaction on two segments of fragment peptides in a liquid phase, in the final liquid chromatography purification step, impurities are not defective peptides lacking one or more amino acids, but are uncondensed partial fragments, the purification difficulty is not caused, in addition, the uncondensed partial peptide fragments can be recycled, and the cost is saved
[Accessed 29 Aug 2023] Eli Lilly and Company 2023
start tablets one week after stopping the 2.4 mg injection